Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Audit to Evaluate the Relation Between Transfusions and Iron Toxicity on Major Outcome Parameters in Patients With Adult Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukaemia (CMML) Treated With Myeloablative Conditioning (MAC) and Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Without Prior Intensive Antileukemic Therapy by the Chronic Malignancies Working Party by the European Society for Blood and Marrow Transplantation

NCT06267898 is registered in ClinicalTrials.gov with European Society for Blood and Marrow Transplantation as lead sponsor.

NCT NCT06267898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06267898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Audit to Evaluate the Relation Between Transfusions and Iron Toxicity on Major Outcome Parameters in Patients With Adult Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukaemia (CMML) Treated With Myeloablative Conditioning (MAC) and Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Without Prior Intensive Antileukemic Therapy by the Chronic Malignancies Working Party by the European Society for Blood and Marrow Transplantation
Lead sponsor
European Society for Blood and Marrow Transplantation
Phase
Observational
Overall status
Completed
Start date
November 1, 2009
Completion date
May 21, 2015
Enrollment
222 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cmml, mds